Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence?  Bryan F. Meyers,

Published byGabriella Singleton Modified over 4 years ago

Similar presentations

Presentation on theme: "Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence?  Bryan F. Meyers,"— Presentation transcript:

1 Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence?  Bryan F. Meyers, MD, MPH, Varun Puri, MD, MBBS, MSCI, Stephen R. Broderick, MD, MPHS, Pamela Samson, MD, Kathleen Keogan, BS, Traves D. Crabtree, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 150, Issue 3, Pages (September 2015) DOI: /j.jtcvs Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

2 STARS accrued 3. 5% of expected, and ROSEL accrued 2. 3%
STARS accrued 3.5% of expected, and ROSEL accrued 2.3%. A pooled analysis remains underpowered. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence?  Bryan F. Meyers,"

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Stephen R. Broderick, MD, MPHS 

Stephen R. Broderick, MD, MPHS 
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,
Lung cancer screening: No more excuses

Lung cancer screening: No more excuses
Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
Ground glass opacity of the lung: The veil that needs lifting

Ground glass opacity of the lung: The veil that needs lifting
National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer  Aalok P. Patel, BS, Traves D. Crabtree,

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer  Aalok P. Patel, BS, Traves D. Crabtree,
John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N
Victor van Berkel, MD, PhD 

Victor van Berkel, MD, PhD 
Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.
Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial  Stacey.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial  Stacey.
Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer  Usman Ahmad, MD, Traves D. Crabtree,

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer  Usman Ahmad, MD, Traves D. Crabtree,
Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer  Pamela Samson, MD, MPHS, Traves.

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer  Pamela Samson, MD, MPHS, Traves.
Shawn S. Groth, MD, Bryan M. Burt, MD 

Shawn S. Groth, MD, Bryan M. Burt, MD 

Similar presentations

Ads by Google